StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) stock

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$7.13−0.24 (-3.26%)

Close on Nov 17, 2026Market cap $382.38MP/E –Yield –

Avalo Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Avalo Therapeutics's total debt was $0 at Dec 31, 2023. For fiscal 2023 it was $0, down 100.0% from the year before. The highest annual figure on record is $32.83M in fiscal 2021.

Annual total debt

PeriodPeriod endValueChange
FY2023Dec 31, 2023$0-100.0%
FY2022Dec 31, 2022$13.49M-58.9%
FY2021Dec 31, 2021$32.83M–
FY2020Dec 31, 2020$0-100.0%
FY2018Dec 31, 2018$15.38M–
FY2017Dec 31, 2017$0-100.0%
FY2016Dec 31, 2016$2.35M-57.7%
FY2015Dec 31, 2015$5.56M-22.9%
FY2014Dec 31, 2014$7.21M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023$0-100.0%
Q3 FY2023Sep 30, 2023$0-100.0%
Q2 FY2023Jun 30, 2023$0-100.0%
Q1 FY2023Mar 31, 2023$10.47M-68.1%
Q4 FY2022Dec 31, 2022$13.49M–
Q3 FY2022Sep 30, 2022$16.50M+7.8%
Q2 FY2022Jun 30, 2022$18.71M+22.1%
Q4 FY2021Dec 31, 2021$32.83M+113.8%
Q4 FY2020Dec 31, 2020$0-100.0%
Q3 FY2019Sep 30, 2019$15.30M-0.6%
Q2 FY2019Jun 30, 2019$15.33M-0.6%
Q1 FY2019Mar 31, 2019$15.35M-0.2%
Q4 FY2018Dec 31, 2018$15.38M–
Q3 FY2018Sep 30, 2018$15.40M–
Q2 FY2018Jun 30, 2018$15.43M+1169.5%
Q1 FY2018Mar 31, 2018$15.38M+415.2%
Q4 FY2017Dec 31, 2017$0-100.0%
Q3 FY2017Sep 30, 2017$0-100.0%
Q2 FY2017Jun 30, 2017$1.22M–
Q1 FY2017Mar 31, 2017$2.98M–
Q4 FY2016Dec 31, 2016$2.35M–
Q3 FY2016Sep 30, 2016$3.19M–

More Avalo Therapeutics figures

See a number that looks wrong?